Amgen’s investigational monoclonal antibody paired with chemotherapy significantly improved overall survival for patients in ...

M.D., executive vice president of Research and Development at Amgen. "These first positive top-line results of an FGFR2b targeted monoclonal antibody from our Phase 3 FORTITUDE-101 study mark a ...

Amgen's Phase 3 trial of bemarituzumab plus chemo met its survival goal in FGFR2b+ gastric cancer, with full data expected ...

Amgen acquired Five Prime in 2021 on the back of the phase 2 FIGHT trial of bemarituzumab, which achieved significant ...

Amgen said on Monday its experimental therapy helped patients with advanced gastric cancer live longer when combined with ...

In a detail-thin announcement, Amgen said that adding bemarituzumab to chemotherapy improved overall survival, though ...

Bemarituzumab targets FGFR2b, which has been found to be overexpressed in approximately 30% of patients with non-HER2 positive gastric cancer.

US biotech major Amgen today announced the Phase III FORTITUDE-101 clinical trial evaluating first-line bemarituzumab plus ...

Amgen & Zai Lab's trial shows bemarituzumab + chemo boosts survival in gastric cancer with FGFR2b. Read more here.

amgen announces positive topline phase 3 results for bemarituzumab in fibroblast growth factor receptor 2b (fgfr2b) positive first-line gastric cancer Provided by PR Newswire Jun 30, 2025, 1:00:00 PM ...

Amgen said on Monday its experimental cancer therapy significantly improved overall survival in patients with advanced ...

amgen announces positive topline phase 3 results for bemarituzumab in fibroblast growth factor receptor 2b (fgfr2b) positive first-line gastric cancer Jun. 30, 2025 9:00 AM ET Amgen Inc. (AMGN) ...